Migraine relief

Sumatriptan treats migraines with or without aura. This drug belongs to a class known as triptans. Triptans work by constricting the widened blood vessels that cause migraine, resulting in alleviation of migraine pain and symptoms. Sumatriptan is generally a well tolerated triptan and is available in a variety of dosage forms such as tablet, nasal spray or injection.

 

How does sumatriptan work?

 

The exact cause of migraine relief is unknown, but it is associated with the widening of blood vessels in the brain. Sumatriptan works by constricting these vessels in the brain, reversing the effects of the migraine, resulting in alleviated migraine symptoms. Sumatriptan takes about 30 minutes to become effective so it is important to take it as soon as you feel the migraine coming on.

 

Taking sumatriptan

 

Sumatriptan works best if you take it as soon as you feel the migraine coming on. It should not be taken before the migraine in the aura phase. A second tablet can be taken 2 to 3 hours after your first tablet if you have not noticed benefits, however no more than 2 tablets should be taken for the same migraine and no more than 2 tablets should be taken in a 24 hour period. Sumatriptan is available as a 50mg or a 100mg tablet, if the 50mg tablet is ineffective, you may find the 100mg tablet more effective. Sumatriptan starts to alleviate symptoms after 30 minutes of taking the tablet.

 

Sumatriptan vs Imigran

 

Sumatriptan is the generic version of Imigran, which is the branded version. Both contain the same active ingredient, which is sumatriptan succinate, both work in the same way and both are just as effective. Although both are medically the same, personal preference is a factor to consider as some people may prefer the branded version to the generic.

 

Alternative medication

 

Not all medication works the same for everyone. Although triptans work in a similar way, you may have to try 3 different ones on 3 different occasions before finding the most effective one for yourself.

Comments are closed